Research analysts at LADENBURG THALM/SH SH initiated coverage on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) in a note issued to investors on Wednesday, reports. The firm set a “buy” rating and a $7.00 price target on the biotechnology company’s stock. LADENBURG THALM/SH SH’s price objective indicates a potential upside of 132.56% from the company’s current price.

Other analysts also recently issued reports about the company. ValuEngine raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.

NASDAQ ORMP traded up $0.01 during trading on Wednesday, reaching $3.01. 570 shares of the company’s stock were exchanged, compared to its average volume of 34,672. The stock has a market cap of $52.14 million, a P/E ratio of -3.49 and a beta of 1.27. The company has a 50 day moving average price of $3.34 and a two-hundred day moving average price of $3.43. Oramed Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $5.05.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.23). Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. The business had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.71 million. As a group, research analysts anticipate that Oramed Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

In other news, Director Leonard Sank bought 25,000 shares of Oramed Pharmaceuticals stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.92 per share, with a total value of $73,000.00. Following the acquisition, the director now owns 364,999 shares of the company’s stock, valued at $1,065,797.08. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders bought a total of 50,817 shares of company stock valued at $164,009 over the last three months. Company insiders own 20.50% of the company’s stock.

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 50.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 158,098 shares of the biotechnology company’s stock after acquiring an additional 53,043 shares during the period. Renaissance Technologies LLC owned 0.91% of Oramed Pharmaceuticals worth $568,000 as of its most recent SEC filing. 4.83% of the stock is currently owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Read More: Market Indexes

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with's FREE daily email newsletter.